Hovilpri is a drug owned by Aicuris Anti-infective Cures Ag. It is protected by 5 US drug patents filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 26, 2032. Details of Hovilpri's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US9340535 | N-[5-(Aminosulfony1)-4-Methyl-1,3-Thiazol-2-Yl]-N-Methyl-2-[4-(2-Pyridinyl)Phenyl]Acetamide Mesylate Monohydrate |
Sep, 2032
(5 years from now) | Active |
| USRE49697 | NA |
Sep, 2032
(5 years from now) | Active |
| US9889124 | Crystalline N-[5-(Aminosulfonyl)-4-Methyl-1,3-Thiazol-2-Yl]-N-Methyl-2-[4-(2-Pyridinyl)Phenyl]Acetamide Mono Mesylate Monohydrate Having A Specific Particle Size Distribution Range And A Specific Surface Area Range For Use In Pharmaceutical Formulations |
Sep, 2032
(5 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9119786 | Crystalline N-[5-(Aminosulfonyl)-4-Methyl-1,3-Thiazol-2-Yl]-N-Methyl-2-[4-(2-Pyridinyl)Phenyl]Acetamide Mono Mesylate Monohydrate Having A Specific Particle Size Distribution Range And A Specific Surface Area Range For Use In Pharmaceutical Formulations |
Sep, 2032
(5 years from now) | Active |
| US8784887 | Pharmaceutical Preparation Of N-[5-(Aminosulfonyl)-4-Methyl-1,3-Thiazol-2-Yl]-N-Methyl-2-[4-(2-Pyridinyl)Phenyl]Acetamide |
Jul, 2029
(2 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Hovilpri is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Hovilpri's family patents as well as insights into
ongoing legal events
on those patents.
Hovilpri's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Hovilpri's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 26, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Hovilpri Generics:
There are no approved generic versions for Hovilpri as of now.
About Hovilpri
Hovilpri is a drug owned by Aicuris Anti-Infective Cures Ag. Hovilpri uses Pritelivir Mesylate as an active ingredient. Hovilpri was launched by Aicuris Anti Infect in 2026.
Approval Date:
Hovilpri was approved by FDA for market use on 09 October, 2026.
Active Ingredient:
Hovilpri uses Pritelivir Mesylate as the active ingredient. Check out other Drugs and Companies using Pritelivir Mesylate ingredient
Dosage:
Hovilpri is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 100MG BASE | TABLET | Prescription | ORAL |
